Trial Search Results
Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration
This study is being done to determine the long-term safety and possible benefits of transplanted Human Central Nervous System Stem Cells (HuCNS-SC) for patients with Geographic Atrophy of Age-Related Macular Degeneration. This long-term follow-up study is limited to those individuals who received a transplant of HuCNS-SC cells into one of their eyes as part of the CL-N01-AMD study. No additional study product will be given in this 4-year long-term follow-up study.
Stanford is currently accepting patients for this trial.
- Biological: Human Central Nervous System Stem Cells
- Must have completed Study CL-N01-AMD
- Must be able to provide written informed consent prior to any study related procedures
- Agree to comply in good faith with all conditions of the study and to attend all
required study visits
- Inability to comply with study procedures or visits
- Since enrolling in Study CL-N01-AMD, have entered, or are about to enter another
investigational study that, in the opinion of the Principal Investigator (PI), might
confound study interpretation.
- Received off-study immunosuppressive agents in the lead-in study or are receiving any
immunosuppressive agents since completing the lead-in study
Ages Eligible for Study
51 Years - N/A
Genders Eligible for Study